GLP-1 medications dominate both media coverage and patient conversations in 2026. Yet roughly 13 FDA-approved weight-loss medications exist. Four non-GLP-1 options form a stable, distinct clinical category: phentermine, phentermine/topiramate ER, naltrexone/bupropion, and orlistat. The newest pipeline approvals remain GLP-1-based, but that does not make this category any less relevant.
This article does not rank these four drugs. It shows how each one maps to a different patient profile. The useful question is not “which non-GLP-1 drug is best?” It is “which mechanism matches this person’s physiology, history, and circumstances?”
The framework is meant for three groups of readers:
- People medically steered away from GLP-1s
- People who tried a GLP-1 and stopped
- People who prefer not to start one
Red Mountain’s earlier class-based clinical guide explains each drug category. This piece builds on that guide and works as a decision tool rather than an encyclopedia entry.
Why a Flat List Fails Patients
“Best to worst” rankings suggest a single hierarchy of efficacy. In reality, these four drugs work through different biological pathways:
- Phentermine: appetite suppression
- Phentermine/topiramate ER: combined appetite and satiety pathways
- Naltrexone/bupropion: reward-pathway modulation
- Orlistat: blocking fat absorption in the gut
A drug that ranks “lower” on an average-efficacy chart can still be the correct first choice for a specific person, because averages describe populations, not individuals. A better approach is a structured framework built on four inputs: exclusion criteria, the type of hunger driving eating, access reality, and tolerance history.
Reframing the Efficacy Data: Trials vs. Real-World Practice
In network meta-analyses, phentermine/topiramate averages about 9.1% body weight loss, and naltrexone/bupropion averages about 4.6%. GLP-1 medications show higher averages in controlled trials.
Real-world data complicates that picture. In one clinic cohort, the following shares of patients reached at least 5% weight loss at six months:
- Phentermine: 87.2%
- Phentermine/topiramate: 67.7%
- Naltrexone/bupropion: 35.3%
Several reasons explain the gap. Trial populations, dosing protocols, and adherence conditions differ from everyday practice. These older drugs also have decades of real-world prescribing experience that trial designs do not capture. “Lower average efficacy” is accurate but incomplete. It reflects how trials are designed more than it predicts any one patient’s result.
The Four Variables That Should Drive Medication Selection
Clinicians apply the following filters in sequence, each one narrowing the field before the next is considered. They are not meant to be ticked off as a checklist.
Filter One: Contraindication-Driven Exclusion
Common reasons a patient may not be a candidate for a GLP-1 include:
- A personal or family history of medullary thyroid carcinoma or MEN2
- Pregnancy or breastfeeding
- Gastroparesis or severe GI disease
- A history of pancreatitis
For these patients, a non-GLP-1 option is not a fallback. It is the clinically appropriate starting point.
Exclusion logic runs in both directions, though. Phentermine and phentermine/topiramate are generally avoided in people with uncontrolled hypertension or cardiovascular disease. Naltrexone/bupropion is generally avoided in people with a seizure disorder or uncontrolled hypertension.
Filter Two: Hedonic vs. Physical Hunger Drivers
Some patients eat mainly because of physical hunger signaling. Others eat mainly because of emotional or reward-based cravings. These two drivers call for different mechanisms:
- Naltrexone/bupropion pairs an opioid receptor antagonist with an antidepressant. It acts on the brain’s reward pathways to reduce cravings tied to pleasure-seeking eating.
- Phentermine and phentermine/topiramate act more directly on appetite and satiety signaling. They suit patients whose main driver is physical hunger.
Determining which driver dominates is a clinical conversation, not a self-diagnosis.
Filter Three: Cost and Access Reality
Access to GLP-1s is limited for many people:
- Employer coverage of GLP-1s for weight loss sits at only 36%.
- Just 8.7% of ACA marketplace carriers cover GLP-1s specifically for obesity.
- Among current and recent GLP-1 users, 56% say the medications are difficult to afford.
Orlistat and generic phentermine are structurally lower-cost options. Cost-effectiveness research has found branded phentermine/topiramate cost-effective, largely because of its lower price. Clinicians also sometimes use off-label, low-cost medications such as metformin or topiramate alone as adjuncts for cost-sensitive patients. These decisions belong to a prescriber, not to self-directed use.
For many patients, cost is not a secondary concern layered on top of the clinical decision. It is part of the clinical decision.
Filter Four: Tolerance History and Prior Discontinuation
Approximately 12% of US adults currently take a GLP-1, and 85% discontinue within two years. Cost and side effects are among the leading reasons.
A patient’s past experience is diagnostic information. GI distress, aversion to injections, or fatigue from ongoing cost all point toward which mechanism to try next.
Body composition matters here too. Lean muscle lost during GLP-1 treatment may not return after the medication is stopped, which raises concerns about sarcopenia. This filter therefore looks forward as well as back. It explains why a patient stopped, and it also helps predict which option they are more likely to stay on.
Matching Mechanism to Patient Phenotype
Peer-reviewed obesity research from Mayo Clinic describes four phenotypes: hungry brain, hungry gut, emotional hunger, and slow burn. In that work, selecting medication by phenotype was associated with better outcomes than standard prescribing.
Hungry Brain: Phentermine/Topiramate
Patients with this phenotype struggle to reach satiety despite eating enough. Phentermine/topiramate ER combines appetite suppression with an effect on satiety pathways. Its real-world result of 67.7% of patients reaching at least 5% weight loss suggests the mechanism holds up outside trial conditions.
Hungry Gut: Orlistat
The original research paired this phenotype with a GLP-1. For patients whose intake is closely tied to digestion and dietary fat, and who cannot or prefer not to use a GLP-1, orlistat is the non-GLP-1 agent that works in the gut. It inhibits intestinal lipase, which reduces how much dietary fat the body absorbs. It acts entirely outside the brain and appetite hormones. Orlistat is also available over the counter, which makes it the most accessible starting point.
Emotional Hunger: Naltrexone/Bupropion
Patients with this phenotype eat in response to stress, mood, or reward-seeking. Naltrexone/bupropion targets those drivers directly and is usually paired with behavioral support and dietary changes. Its trial average of 4.6% and its real-world rate of 35.3% reaching at least 5% loss describe a tool matched to one specific driver. It is not a weaker version of the other options.
Slow Burn: Phentermine
Patients with a lower resting metabolic rate may benefit from appetite suppression combined with structured activity. Phentermine is the oldest and most widely used anti-obesity medication, with average weight loss of 5 to 10% of body weight. The FDA approved it for short-term use, but obesity medicine prescribers widely use it long-term. In the cohort data, 87.2% of patients reached at least 5% loss, which shows the drug remains clinically relevant nearly 70 years after approval.
When Non-GLP-1 Is the Rational First Choice
For patients with contraindications, cost barriers, or prior intolerance, non-GLP-1 drugs are a rational first-line choice, not a consolation prize. With employer coverage at 36% and marketplace coverage at 8.7%, starting with a non-GLP-1 option is often the more sustainable path. For patients coming off a GLP-1, these medications can also help maintain progress and limit regain.
Where Medication Fits in the Larger Plan
At Red Mountain, choosing a medication is the starting point of the Foundation stage of care, not the entire plan. The Foundation stage looks for the root cause of why earlier efforts stopped working. It does this through metabolic assessment, lab work, and nutrition strategy alongside any medication.
Medication of any class is treated as one tool among several. Supporting structure helps minimize side effects, preserve muscle mass, and maintain nutrient balance. Later stages build on that foundation:
- Function: hormone optimization, body composition, and support for energy, mood, and day-to-day function as progress builds
- Confidence: aligning appearance with how patients feel through conservative, subtle aesthetic care
- Longevity: ongoing monitoring and maintenance
In-person clinicians and more than 30 years of real-world patient outcomes allow this kind of phenotype-based matching to be applied responsibly.
Conclusion
Non-GLP-1 medications are not a lesser category. They are four distinct mechanistic tools, each suited to different physiology, history, and circumstances. Efficacy averages tell only part of the story. Real-world adherence, contraindications, hunger-driver type, and access are equally valid clinical inputs. Informed medication selection is the first step in a longer process of metabolic correction, not a one-time decision made in isolation.
Is a Non-GLP-1 Option the Right Fit?
Readers can weigh their own profile against this framework: any contraindications, the main driver of their eating, their cost and access constraints, and how they have tolerated medications in the past. If this sounds familiar, a consult is usually the next step. That is where phenotype and circumstance matching happens under clinical oversight rather than guesswork. The goal is to identify the right starting tool within a longer plan for sustainable metabolic health, not to sell a single medication.
